Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for In Vivo nonhuman primate studies

Gregory Q. Del Prete, Matthew Scarlotta, Laura Newman, Carolyn Reid, Laura M. Parodi, James D. Roser, Kelli Oswald, Preston A. Marx, Christopher J. Miller, Ronald C. Desrosiers, Dan H. Barouch, Ranajit Pal, Michael Piatak, Elena Chertova, Luis D. Giavedoni, David H. O'Connor, Jeffrey D. Lifson, Brandon F. Keele

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Simian immunodeficiency virus (SIV) stocks for in vivo nonhuman primate models of AIDS are typically generated by transfection of 293T cells with molecularly cloned viral genomes or by expansion in productively infected T cells. Although titers of stocks are determined for infectivity in vitro prior to in vivo inoculation, virus production methods may differentially affect stock features that are not routinely analyzed but may impact in vivo infectivity, mucosal transmissibility, and early infection events. We performed a detailed analysis of nine SIV stocks, comprising five infection-derived SIVmac251 viral swarm stocks and paired infection- and transfected-293T-cell-derived stocks of both SIVmac239 and SIVmac766. Representative stocks were evaluated for (i) virus content, (ii) infectious titer, (iii) sequence diversity and polymorphism frequency by single-genome amplification and 454 pyrosequencing, (iv) virion-associated Env content, and (v) cytokine and chemokine content by 36-plex Luminex analysis. Regardless of production method, all stocks had comparable particle/infectivity ratios, with the transfected-293T stocks possessing the highest overall virus content and infectivity titers despite containing markedly lower levels of virion-associated Env than infection-derived viruses. Transfected-293T stocks also contained fewer and lower levels of cytokines and chemokines than infection-derived stocks, which had elevated levels of multiple analytes, with substantial variability among stocks. Sequencing of the infection-derived SIVmac251 stocks revealed variable levels of viral diversity between stocks, with evidence of stock-specific selection and expansion of unique viral lineages. These analyses suggest that there may be underappreciated features of SIV in vivo challenge stocks with the potential to impact early infection events, which may merit consideration when selecting virus stocks for in vivo studies.

Original languageEnglish (US)
Pages (from-to)4584-4595
Number of pages12
JournalJournal of Virology
Volume87
Issue number8
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
transfection
Primates
Transfection
Infection
infection
Viruses
pathogenicity
viruses
HEK293 Cells
Chemokines
Virion
chemokines
virion
Cytokines
cytokines
Viral Genome
Virus Diseases
genome

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for In Vivo nonhuman primate studies. / Del Prete, Gregory Q.; Scarlotta, Matthew; Newman, Laura; Reid, Carolyn; Parodi, Laura M.; Roser, James D.; Oswald, Kelli; Marx, Preston A.; Miller, Christopher J.; Desrosiers, Ronald C.; Barouch, Dan H.; Pal, Ranajit; Piatak, Michael; Chertova, Elena; Giavedoni, Luis D.; O'Connor, David H.; Lifson, Jeffrey D.; Keele, Brandon F.

In: Journal of Virology, Vol. 87, No. 8, 04.2013, p. 4584-4595.

Research output: Contribution to journalArticle

Del Prete, GQ, Scarlotta, M, Newman, L, Reid, C, Parodi, LM, Roser, JD, Oswald, K, Marx, PA, Miller, CJ, Desrosiers, RC, Barouch, DH, Pal, R, Piatak, M, Chertova, E, Giavedoni, LD, O'Connor, DH, Lifson, JD & Keele, BF 2013, 'Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for In Vivo nonhuman primate studies', Journal of Virology, vol. 87, no. 8, pp. 4584-4595. https://doi.org/10.1128/JVI.03507-12
Del Prete, Gregory Q. ; Scarlotta, Matthew ; Newman, Laura ; Reid, Carolyn ; Parodi, Laura M. ; Roser, James D. ; Oswald, Kelli ; Marx, Preston A. ; Miller, Christopher J. ; Desrosiers, Ronald C. ; Barouch, Dan H. ; Pal, Ranajit ; Piatak, Michael ; Chertova, Elena ; Giavedoni, Luis D. ; O'Connor, David H. ; Lifson, Jeffrey D. ; Keele, Brandon F. / Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for In Vivo nonhuman primate studies. In: Journal of Virology. 2013 ; Vol. 87, No. 8. pp. 4584-4595.
@article{c45d923ff73d4926b49318378b0eb882,
title = "Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for In Vivo nonhuman primate studies",
abstract = "Simian immunodeficiency virus (SIV) stocks for in vivo nonhuman primate models of AIDS are typically generated by transfection of 293T cells with molecularly cloned viral genomes or by expansion in productively infected T cells. Although titers of stocks are determined for infectivity in vitro prior to in vivo inoculation, virus production methods may differentially affect stock features that are not routinely analyzed but may impact in vivo infectivity, mucosal transmissibility, and early infection events. We performed a detailed analysis of nine SIV stocks, comprising five infection-derived SIVmac251 viral swarm stocks and paired infection- and transfected-293T-cell-derived stocks of both SIVmac239 and SIVmac766. Representative stocks were evaluated for (i) virus content, (ii) infectious titer, (iii) sequence diversity and polymorphism frequency by single-genome amplification and 454 pyrosequencing, (iv) virion-associated Env content, and (v) cytokine and chemokine content by 36-plex Luminex analysis. Regardless of production method, all stocks had comparable particle/infectivity ratios, with the transfected-293T stocks possessing the highest overall virus content and infectivity titers despite containing markedly lower levels of virion-associated Env than infection-derived viruses. Transfected-293T stocks also contained fewer and lower levels of cytokines and chemokines than infection-derived stocks, which had elevated levels of multiple analytes, with substantial variability among stocks. Sequencing of the infection-derived SIVmac251 stocks revealed variable levels of viral diversity between stocks, with evidence of stock-specific selection and expansion of unique viral lineages. These analyses suggest that there may be underappreciated features of SIV in vivo challenge stocks with the potential to impact early infection events, which may merit consideration when selecting virus stocks for in vivo studies.",
author = "{Del Prete}, {Gregory Q.} and Matthew Scarlotta and Laura Newman and Carolyn Reid and Parodi, {Laura M.} and Roser, {James D.} and Kelli Oswald and Marx, {Preston A.} and Miller, {Christopher J.} and Desrosiers, {Ronald C.} and Barouch, {Dan H.} and Ranajit Pal and Michael Piatak and Elena Chertova and Giavedoni, {Luis D.} and O'Connor, {David H.} and Lifson, {Jeffrey D.} and Keele, {Brandon F.}",
year = "2013",
month = "4",
doi = "10.1128/JVI.03507-12",
language = "English (US)",
volume = "87",
pages = "4584--4595",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for In Vivo nonhuman primate studies

AU - Del Prete, Gregory Q.

AU - Scarlotta, Matthew

AU - Newman, Laura

AU - Reid, Carolyn

AU - Parodi, Laura M.

AU - Roser, James D.

AU - Oswald, Kelli

AU - Marx, Preston A.

AU - Miller, Christopher J.

AU - Desrosiers, Ronald C.

AU - Barouch, Dan H.

AU - Pal, Ranajit

AU - Piatak, Michael

AU - Chertova, Elena

AU - Giavedoni, Luis D.

AU - O'Connor, David H.

AU - Lifson, Jeffrey D.

AU - Keele, Brandon F.

PY - 2013/4

Y1 - 2013/4

N2 - Simian immunodeficiency virus (SIV) stocks for in vivo nonhuman primate models of AIDS are typically generated by transfection of 293T cells with molecularly cloned viral genomes or by expansion in productively infected T cells. Although titers of stocks are determined for infectivity in vitro prior to in vivo inoculation, virus production methods may differentially affect stock features that are not routinely analyzed but may impact in vivo infectivity, mucosal transmissibility, and early infection events. We performed a detailed analysis of nine SIV stocks, comprising five infection-derived SIVmac251 viral swarm stocks and paired infection- and transfected-293T-cell-derived stocks of both SIVmac239 and SIVmac766. Representative stocks were evaluated for (i) virus content, (ii) infectious titer, (iii) sequence diversity and polymorphism frequency by single-genome amplification and 454 pyrosequencing, (iv) virion-associated Env content, and (v) cytokine and chemokine content by 36-plex Luminex analysis. Regardless of production method, all stocks had comparable particle/infectivity ratios, with the transfected-293T stocks possessing the highest overall virus content and infectivity titers despite containing markedly lower levels of virion-associated Env than infection-derived viruses. Transfected-293T stocks also contained fewer and lower levels of cytokines and chemokines than infection-derived stocks, which had elevated levels of multiple analytes, with substantial variability among stocks. Sequencing of the infection-derived SIVmac251 stocks revealed variable levels of viral diversity between stocks, with evidence of stock-specific selection and expansion of unique viral lineages. These analyses suggest that there may be underappreciated features of SIV in vivo challenge stocks with the potential to impact early infection events, which may merit consideration when selecting virus stocks for in vivo studies.

AB - Simian immunodeficiency virus (SIV) stocks for in vivo nonhuman primate models of AIDS are typically generated by transfection of 293T cells with molecularly cloned viral genomes or by expansion in productively infected T cells. Although titers of stocks are determined for infectivity in vitro prior to in vivo inoculation, virus production methods may differentially affect stock features that are not routinely analyzed but may impact in vivo infectivity, mucosal transmissibility, and early infection events. We performed a detailed analysis of nine SIV stocks, comprising five infection-derived SIVmac251 viral swarm stocks and paired infection- and transfected-293T-cell-derived stocks of both SIVmac239 and SIVmac766. Representative stocks were evaluated for (i) virus content, (ii) infectious titer, (iii) sequence diversity and polymorphism frequency by single-genome amplification and 454 pyrosequencing, (iv) virion-associated Env content, and (v) cytokine and chemokine content by 36-plex Luminex analysis. Regardless of production method, all stocks had comparable particle/infectivity ratios, with the transfected-293T stocks possessing the highest overall virus content and infectivity titers despite containing markedly lower levels of virion-associated Env than infection-derived viruses. Transfected-293T stocks also contained fewer and lower levels of cytokines and chemokines than infection-derived stocks, which had elevated levels of multiple analytes, with substantial variability among stocks. Sequencing of the infection-derived SIVmac251 stocks revealed variable levels of viral diversity between stocks, with evidence of stock-specific selection and expansion of unique viral lineages. These analyses suggest that there may be underappreciated features of SIV in vivo challenge stocks with the potential to impact early infection events, which may merit consideration when selecting virus stocks for in vivo studies.

UR - http://www.scopus.com/inward/record.url?scp=84875770562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875770562&partnerID=8YFLogxK

U2 - 10.1128/JVI.03507-12

DO - 10.1128/JVI.03507-12

M3 - Article

C2 - 23408608

AN - SCOPUS:84875770562

VL - 87

SP - 4584

EP - 4595

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 8

ER -